JAKARTA - The International Pharmaceutical Manufacturers Group (IPMG), an association representing 25 research-based multinational pharmaceutical companies in Indonesia, today announced the composition of the Board of Directors for the period 2026-2028.
IPMG member companies have again entrusted by appointing Merck Indonesia President Director Evie Yulin as Chairman of IPMG and Merck Sharp & Dohme Indonesia President Director George Stylianou as Vice Chairman of IPMG.
The members believe that their leadership will continue to have a meaningful impact on patients in Indonesia, the health system, and the industry in advancing IPMG's vision and mission.
"I am honored and enthusiastic to continue IPMG's advocacy efforts in increasing the availability and access to innovative medicines in Indonesia. Currently, only about 9 percent of innovative drugs are available in Indonesia and only about 2 percent can be accessed through public financing. Bridging this gap remains IPMG's top priority, and through strong collaboration, we are committed to ensuring that more patients can receive the benefits of innovative medicines, strengthen public health, and support the achievement of the Indonesia Emas 2045 vision," said IPMG Chairman Evie Yulin in a written statement, Wednesday, April 1.
The newly approved Board of Directors presents leaders with various backgrounds of expertise, including the field of Health Technology Assessment (HTA), pricing and procurement mechanisms, regulatory frameworks, ethics, patient safety and safety, and health investments. This reflects a coordinated approach to strengthening the Indonesian health ecosystem.
Encouraging Access to Innovative Drugs
IPMG remains committed to increasing the availability and access to innovative medicines for patients in Indonesia. Although there has been progress, access is still limited, which underscores the importance of continued collaboration.
IPMG Executive Director Ani Rahardjo said that his party encouraged the creation of a predictable and transparent policy environment, strengthening the implementation of Health Technology Assessment (HTA) including through the stakeholder-led submissions (SLS) mechanism, the development of sustainable pricing and procurement mechanisms, and stronger coordination between registration, financing, and patient access pathways.
"IPMG will continue to play a constructive role in supporting policy dialogue and strengthening implementation in line with national health priorities. We remain open to collaborating to build a more resilient health system and improve Indonesia's competitiveness," said Ani.
IPMG upholds ethical standards as the foundation of trust, patient welfare, and a well-functioning health system. Efforts to prevent corruption and responsible interactions throughout the health ecosystem are key in maintaining integrity, expanding patient access to quality medicines, and protecting public interests.
IPMG also refers to the Code of Practice of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) which regulates interactions with health workers, medical institutions, and patient organizations globally.
Going forward, IPMG continues to be committed to working collaboratively with all stakeholders in strengthening the Indonesian health system, improving patient health outcomes, and promoting national competitiveness.
IPMG believes that health is not a cost, but a strategic investment - which is essential to realize a healthier, more productive, and globally competitive Indonesia.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
